SINGAPORE, 6 November 2026 — SINGAUTO today announced the deployment schedule for customised all-electric driverless cold-chain vehicles [CW1.1]intended for a global leading pharmaceutical company’s manufacturing facility in Jiangsu, China. On-site installation is scheduled for the fourth quarter of 2026, followed by on-site commissioning and on-site vehicle acceptance in the first quarter of 2027.
In August 2026, SINGAUTO’s authorised partner in China signed a purchase agreement for the customised vehicles. Based on SINGAUTO’s S1 platform, the vehicles combine driverless technology, intelligent fleet management, precision temperature control and automated infrastructure connectivity to support the movement of temperature-sensitive materials within the facility.
“Pharmaceutical cold-chain logistics demands reliable temperature control, end-to-end data traceability, multiple layers of safety and close integration with manufacturing infrastructure. This project represents an important commercial step for SINGAUTO as we expand our offering to pharmaceutical and industrial customers internationally. We are focused on delivering an integrated driverless cold-chain solution tailored to the facility’s operating requirements”, said a SINGAUTO spokesperson.
Supporting Pharmaceutical Manufacturing Logistics
Pharmaceutical facilities require frequent transfers of temperature-sensitive raw materials, intermediate products and finished medicines under stringent quality controls. SINGAUTO’s solution is designed to reduce manual handling and human error while strengthening transport records and coordination across factory operations.
The planned deployment connects vehicles with loading docks, automated access doors and charging infrastructure. Its digital monitoring and fleet management capabilities are intended to support Good Manufacturing Practice (GMP) traceability requirements and the facility’s broader automation objectives.
Four Core Technologies Driving Driverless Cold-Chain Vehicle Innovation
SINGAUTO’s driverless cold-chain vehicles integrate four technology systems designed for the operational demands of pharmaceutical manufacturing:
1. SVCS Intelligent Fleet Management Platform
A centralised platform combines real-time monitoring, automated dispatch, comprehensive data collection and secure audit trails to support GMP traceability requirements. Vehicle-mounted and loading-dock terminals enable task coordination, remote intervention and automated safety alerts.
2. Advanced Driverless Vehicle System
A multi-redundant safety architecture incorporates LiDAR, radar, AI-enabled cameras, infrared sensors and high-precision real-time kinematic (RTK) positioning. These systems support driverless navigation, obstacle detection, precision docking and automated cargo handling within manufacturing environments.
3. Intelligent Infrastructure Integration
A dedicated vehicle-to-infrastructure communication system coordinates vehicle movements with automated facility access doors. This enables hands-free transit while helping preserve separation between temperature-controlled manufacturing zones.
4. Automated Charging and Energy Management
An integrated system supports automatic docking and charging, centralised battery monitoring and off-peak charging. These capabilities are designed to support continuous fleet operations with reduced manual intervention.
The all-electric vehicles produce zero tailpipe emissions and feature independently temperature-controlled cargo compartments. Continuous digital monitoring of routes, cargo temperatures and equipment status is designed to provide operational records supporting pharmaceutical traceability and compliance processes.
Global Commercialisation Strategy
SINGAUTO plans to expand its driverless cold-chain offering across pharmaceutical manufacturing, life sciences and industrial logistics. Its strategy centres on four priorities:
i. Integrated customer delivery. Provide vehicle hardware, the SVCS platform, infrastructure integration and operations and maintenance support as a coordinated solution tailored to each site.
ii. Platform scalability. Enhance multi-vehicle dispatch and remote fleet management across multiple facilities, with configurations adapted to local operating and compliance requirements.
iii. Broader applications. Pursue opportunities at biologics and vaccine manufacturing sites, pharmaceutical campuses and cold chain logistics parks, while expanding the vehicle portfolio to address different payload and workflow requirements.
iv. International partnerships. Work with system integrators and engineering service providers to support local implementation,servicing and market access.[CW2.1]
About SINGAUTO
Headquartered in Singapore, SINGAUTO is a green intelligent cold-chain technology company focused on developing refrigerated commercial electric vehicles and related solutions for customers in the cold-chain logistics industry, including transportation and logistics service providers serving food products, pharmaceuticals and other temperature-sensitive goods.
This press release contains forward-looking statements within the meaning of the U.S. federal securities laws, including statements regarding anticipated vehicle delivery timelines, product capabilities and future business plans. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including delays in manufacturing, testing or validation. SINGAUTO undertakes no obligation to update these statements except as required by law.
